-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $300

Benzinga·10/08/2026 20:54:01
Listen to the news
JP Morgan analyst Chris Schott maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $285 to $300.